370 related articles for article (PubMed ID: 14529398)
1. Cyclooxygenase-2 biology.
Clària J
Curr Pharm Des; 2003; 9(27):2177-90. PubMed ID: 14529398
[TBL] [Abstract][Full Text] [Related]
2. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
3. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers.
Khanapure SP; Garvey DS; Janero DR; Letts LG
Curr Top Med Chem; 2007; 7(3):311-40. PubMed ID: 17305573
[TBL] [Abstract][Full Text] [Related]
4. COX-1 and COX-2 in health and disease.
Adelizzi RA
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S7-12. PubMed ID: 10643175
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2: a therapeutic target.
Turini ME; DuBois RN
Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
van der Bijl P; van der Bijl P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility.
Cronstein BN
Cleve Clin J Med; 2002; 69 Suppl 1():SI13-9. PubMed ID: 12086289
[TBL] [Abstract][Full Text] [Related]
8. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
9. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies.
Tapiero H; Ba GN; Couvreur P; Tew KD
Biomed Pharmacother; 2002 Jul; 56(5):215-22. PubMed ID: 12199620
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase enzymes in allergic inflammation and asthma.
Carey MA; Germolec DR; Langenbach R; Zeldin DC
Prostaglandins Leukot Essent Fatty Acids; 2003; 69(2-3):157-62. PubMed ID: 12895598
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cyclo-oxygenase-2.
Stack E; DuBois RN
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):787-800. PubMed ID: 11566041
[TBL] [Abstract][Full Text] [Related]
13. Cox-2-specific inhibitors: definition of a new therapeutic concept.
Verburg KM; Maziasz TJ; Weiner E; Loose L; Geis GS; Isakson PC
Am J Ther; 2001; 8(1):49-64. PubMed ID: 11304658
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological analysis of cyclooxygenase-1 in inflammation.
Smith CJ; Zhang Y; Koboldt CM; Muhammad J; Zweifel BS; Shaffer A; Talley JJ; Masferrer JL; Seibert K; Isakson PC
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13313-8. PubMed ID: 9789085
[TBL] [Abstract][Full Text] [Related]
15. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
Gaddi A; Cicero AF; Pedro EJ
Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
[TBL] [Abstract][Full Text] [Related]
16. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
[TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibition and the control of pain.
Kiefer W; Dannhardt G
Curr Opin Investig Drugs; 2002 Sep; 3(9):1348-58. PubMed ID: 12498012
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors.
Kulkarni SK; Jain NK; Singh A
Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):291-8. PubMed ID: 11031730
[TBL] [Abstract][Full Text] [Related]
19. [The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis].
Stańczyk J; Kowalski ML
Pol Merkur Lekarski; 2001 Nov; 11(65):438-43. PubMed ID: 11852819
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with cyclooxygenase-2 inhibitors.
van Ryn J; Pairet M
Inflamm Res; 1999 May; 48(5):247-54. PubMed ID: 10391112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
